PFE and BMY Related Headlines

Go Back

Oct 1, 2014 08:17AM Portola Pharma (PTLA) Reports Andexanet Alfa Phase 3 Met Primary Endpoint
Aug 21, 2014 01:32PM Bristol-Myers Squibb (BMY), Pfizer (PFE) Receive FDA Approval of Eliquis sNDA for DVT and PE
Jul 17, 2014 08:07AM Bristol-Myers Squibb (BMY), Pfizer (PFE) Entroll First Patient into Eliquis Phase IV
Jun 27, 2014 07:04AM Bristol-Myers Squibb's (BMY) Daklinza Receives Positive CHMP Opinion
May 14, 2014 03:13PM Drugs Stocks on Watch Ahead of ASCO Abstracts Release
Mar 14, 2014 01:04PM Bristol-Myers (BMY), Pfizer (PFE) Report FDA Approval of Eliquis sNDA
Jan 13, 2014 08:17AM Portola Pharmaceuticals (PTLA) Enters Second Collaboration Deal with Bristol-Myers (BMY)
Dec 19, 2013 05:02PM Bristol-Myers (BMY), Pfizer (PFE) sNDA for ELIQUIS Approved by FDA

PFE and BMY Related Press Releases

Go Back

Oct 1, 2014 08:00AM Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance
Sep 22, 2014 08:00AM Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers
Aug 30, 2014 05:15AM Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Pa
Aug 21, 2014 01:31PM U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Aug 20, 2014 08:00AM Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014
Jan 13, 2014 08:00AM Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With

PFE and BMY Related SEC Filings

Go Back